Professional background

Karl Peggs is a professor of transplant science and cancer immunotherapy, scientific director NIHR blood and transplant research unit for stem cells and immunotherapies, and clinical and scientific director of the Sir Naim Dangoor Centre for Cellular Therapy, UCLH.

Karl completed his medical training at Cambridge and Oxford Universities. Following specialisation in haematology, he spent three years developing cellular therapies for viruses at UCL. After taking the position head of adult stem cell transplantation services at UCLH, he spent three years at MSKCC in the laboratory of Dr James Allison, contributing to the body of work underpinning checkpoint blockade that led to the Nobel Prize for Medicine in 2018.

He runs a joint research laboratory with Professor Sergio Quezada in the UCL Cancer Institute and is co-founder of the UCL spinout company Achilles Therapeutics. His research interests include viral infections, adoptive cellular therapies, and regulatory checkpoint-directed immune-therapeutics. More recently he has established the clinical translational side of the academic CAR-T cell programme at UCLH.

Research interests

• Cellular therapies
• Stem cell transplantation
• Viral infections
• Hodgkin and non-Hodgkin's lymphomas


Most recent publications

Solomon I, Amann M, Goubier A, Vargas F, Zervas D, Qing C, Henry J, ?ledzi?ska A, Werner Sunderland M, Demane D, Clancy J, Georgiou A, Salimu J, Merchiers P, Brown M, Flury R, Eckmann J, Murga C, Sam J, Sutmuller R, Peggs KS, Quezada S. Tumor control by novel CD25-targeting antibodies preserving IL-2 signaling on effector T cells. 2020. Nat Cancer. In press.

Chemaly RF, El Haddad L, Winston DJ, Rowley SD, Mulane KM, Chandrasekar P, Avery RK, Hari P, Peggs KS, Kumar D, Nath R, Ljungman P, Mossad SB, Dadwal SS, Blanchard T, Shah DP, Jiang Y, Ariza-Heredia E. CMV cell-mediated immunity and CMV infection after allogeneic hematopoietic cell transplantation: the REACT study. Clin Infect Dis. 2020. In press.

O’Reilly M, Peggs KS. Off-the-shelf EBV-specific T Cell Immunotherapy for EBV-associated PTLD. Transplantation. 2020. In press.

Cuadrado MM, Szydlo RM, Watts M, Patel N, Renshaw H, Dorman J, Lowdell M, Ings S, Anthias C, MadrigalA, Mackinnon S, Kottaridis P, Carpenter B, HoughR, Morris E, Thomson K, Peggs KS, Chakraverty R. Predictors of recovery following allogeneic CD34+-selected cell infusion without conditioning to correct poor graft function. Haematologica.2020. https://doi: 10.3324/haematol.2019.226340.

Shafat MS, Mehra V, Peggs KS, Claire R. Cellular therapeutic approaches to cytomegalovirus infection following allogeneic stem cell transplantation. Frontiers in Immunology. 2020 July;

AbdulJabbar K, Raza SEA, Rosenthal R, Jamal-Hanjani M, Veeriah S, Akarca A, Lund T, Moore DA, Salgado R, Al Bakir M, Zapata L, Hiley CT, Officer L, Sereno M, Smith CR, Loi S, Hackshaw A, Marafioti T, Quezada SA, McGranahan N, Le Quesne J; TRACERx Consortium, Swanton C, Yuan Y. Geospatial immune variability illuminates differential evolution of lung adenocarcinoma. Nat Med. 2020 Jul;26(7):1054-1062.

Ghorani E, Reading JL, Henry JY, de Massy MR, Rosenthal R, Turati V, Joshi K, Furness AJS, Aissa AB, Saini SK, Ramskov S, Georgiou A, Sunderland MW, Wong YNS, De Mucha MV, Day W, Galvez-Cancino F, Becker PD, Uddin I, Ismail M, Ronel T, Woolston A, Jamal-Hanjani M, Veeriah S, Birkbak NJ, Wilson GA, Litchfield K, Conde L, Guerra-Assunção JA, Blighe K, Biswas D, Salgado R, Lund T, Al Bakir M, Moore DA, Hiley CT, Loi S, Sun Y, Yuan Y, AbdulJabbar K, Turajilic S, Herrero J, Enver T, Hadrup SR, Hackshaw A, Peggs KS, McGranahan N, Chain B, Swanton C, Quezada SA. The T cell differentiation landscape is shaped by tumour mutations in lung cancer. Nat Cancer. 2020 May;1(5):546-561.

López S, Lim EL, Horswell S, Haase K, Huebner A, Dietzen M, Mourikis TP, Watkins TBK, Rowan A, Dewhurst SM, Birkbak NJ, Wilson GA, Van Loo P, Jamal-Hanjani M; TRACERx Consortium, Swanton C, McGranahan N. Interplay between whole-genome doubling and the accumulation of deleterious alterations in cancer evolution. Nat Genet. 2020 Mar;52(3):283-293.

O’Reilly M, Roddie C, Marzolini MAV, Rodriguez-Justo M, Pomplun S, Pule M, Peggs KS. Trafficking of CAR-T cells to sites of subclinical leukaemia cutis. Lancet Oncol. 2020 Mar;21(3):e179.

A, Vila de Mucha M, Bergerhoff K, HotblackA, Demane DF, Ghorani E, Arakrca A,Marzolini MAV, Solomon I, Vargas FA, Pule M, Ono M, Seddon B, Kassiotis G, Marafioti T, Ariyan CE, Korn T, Lord GM, Stauss H, Jenner RG, Peggs KS*, Quezada SA. Regulatory T cells restrain IL-2- and Blimp-1-dependent acquisition of cytotoxic function by CD4+ T cells. Immunity. 2020 Jan 14;52(1):151-166.

Das Gupta E, Thomson KJ, Bloor A, Clark A, Mackinnon S, Kayani I, Clifton-Hadley L, Patrick P, El-Mehidi N, Lawrie A, KirkwoodAA, Russell N, Linch DC, Peggs KS. Allogeneic stem cell transplantation in transplant-naïve patients with Hodgkin Lymphoma: a single-arm, multi-centre study. Blood Adv. 2019 Dec 23;3(24):4264-4270.

Sellar RS, Mehra V, Fox TA, Grigg A, Kulasekararaj A, Sarma A, de Lavallade H, McLornan D, Raj K, Mufti GJ, Pagliuca A, Mackinnon S, Chakraverty R, Fielding AK, Carpenter B, Kottaridis PD, Khwaja A, Peggs KS, Thomson KJ, Morris EC, Potter VT. Comparative analysis of melphalan versus busulphan T-cell deplete conditioning using alemtuzumab in unrelated donor stem cell transplantation for acute myeloid leukaemia. Br J Haematol. 2019 Oct;187(1):e20-e24.

Joshi K, Ismail M, de Massy MR, Reading J, Uddin I, Woolston A …. Peggs KS, McGranahan N, Swanton S, Quezada SA, Chain B. Ubiquitous and region-specific T cell receptor enrichment reflects neoantigen distribution in NSCLC: TRACERx lung. Nat Med. 2019 Oct;25(10):1549-1559.

Biswas D, Birkbak NJ, Rosenthal R, Hiley CT, Lim EL, Papp K, … Swanton C, TRACERx Consortium. A clonal expression biomarker associates with lung cancer mortality. Nat Med. Oct;25(10):1540-1548.

Chemi F, Rothwell DG, McGranahan N, Gulati S, Abbosh C, Pearce SP, Zhou C, Wilson GA, … Swanton C, Dive C; TRACERx Consortium. Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat Med. 2019 Oct;25(10): 1534-1539.

Ros-Soto J, Snowden JA, Salooja N, Gilleece M, Parker A, Greenfield DM, Anthias C, Alfred A, Harrington A, Peczynski C, Peggs K, Madrigal A, Basak GW, Schoemans H. Current practice in vitamin D management in allogeneic haematopoietic stem cell transplantation: a survey by the Transplant Complications Working Party of the EBMT. Biol Blood Marrow Transplant. 2019 Oct;25(10):2079-2085.

Marzolini MAV, Jaunmuktane Z, Roddie C, Chiodini P, Peggs KS. Toxoplasmosis initially presenting as neurological sequelae of chimeric antigen receptor (CAR)-T cell therapy. Lancet Infect Dis. 2019 Jul;19(7):788.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldejerou L, Gardner RA, Frey N, Curran KJ, Peggs K. Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for cytokine release syndrome and neurological toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638.

Rosenthal R, Cadieux EL, Salgado R … Swanton C, on behalf of the TRACERx consortium. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019 Mar;567(7749):479-485.

Chemaly RF,Hill JA, Voigt S, Peggs.KS. In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review. Antiviral Research. 2019 Mar;163:50-58.

Rule S, Cook G, Russell NH, Hunter A, Robinson S, Morley N, Sureda A, Patrick P, Clifton-Hadley L, Adedayo T, Kirkwood A, Peggs KS. Allogeneic stem cell transplantation as part of front-line therapy for mantle cell lymphoma. Br J Haematol. 2019 Mar;184(6):999-1005.

Quezada SA, Peggs KS. Lost in translation: deciphering the mechanism of action of anti-human CTLA-4. Clin Cancer Res. 2019 Feb;25(4):1130-1132.

Miller PD, de Silva TI, Hayley L, Anthias C, Hoschler K, Goddard K, Peggs K, Madrigal A, Snowden JA. A comparison of viral microneutralization and haemagglutination inhibition assays as measures of seasonal inactivated influenza vaccine immunogenicity in the first year after reduced intensity conditioning, lymphocyte-deplete allogeneic haematopoietic stem cell transplant. Vaccine. 2019 Jan;37(3):452-457.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Blaise D, Peggs KS, et al. Brentuximab Vedotin for recurrent Hodgkin lymphoma after allogeneic hematopoietic cell transplantation: a report from the EBMT Lymphoma Working Party. Cancer. 2019 Jan;125(1):90-98.

Marzolini MAV, Peggs K. Cytotoxic T cells for infections: from donor specific to ‘off the shelf’. In Cell and Gene Therapies (Advances and Controversies in Hematopoietic Transplantation and Cell Therapy). Ed. Perales MA, Abutalib SA, Bollard C. Springer 2018 Dec; 137-157. (

Wong SYN, Joshi K, Khetrapal P, Ismail M, Reading J, Georgiou A, Sunderland MW, Ben Aissa A, Furness A, Ghorani E, Oakes T, Uddin I, Tan WS, Feber A, McGovern U, Swanton C, Freeman A, Marafioti T, Kelly J, Briggs T, Powles T, Peggs KS, Chain B, Linch M, Quezada SA. Urine derived lymphocytes as a non-invasive measure of the tumor immune microenvironment in muscle invasive bladder cancer. J Exp Med. 2018 Nov;215(11):2748-2759.

Furness AJS, Arce Vargas F, Litchfield K, Rosenthal R, Gore M, Larkin J, Turajlic S, Swanton C, Peggs K, Quezada S. Mechanism informs precision: In vivo determinants of response to anti-CTLA-4 antibodies. Ann Oncol. 2018 Sep;29 Suppl 6:vi35.

Miller PD, Forster AS, de Silva TI, Hayley L, Anthias C, Mayhew M, Klammer M, Paskar S, Hurst E, Peggs K, Madrigal A, Snowden JA. Sociodemographic and psychological determinants of influenza vaccine intention amongst recipients of autologous and allogeneic haematopoietic stem cell transplant: a cross-sectional survey of UK transplant recipients using a modified health belief model. BMJ Open. 2018 Aug;8(8):e021222.

Werner Sunderland M, Peggs KS. Successful translation and future prospects of TALEN editing for leukemia patients. Expert Opin Biol Ther. 2018 Jun 14:1-2.

Reading JL, Gálvez-Cancino F, Swanton C, Lladser A, Peggs KS, Quezada SA. The function and dysfunction of memory CD8+ T cells in tumor immunity. Immunol Rev. 2018 May;283(1):194-212.

Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, Finke J, Poiré X, Maillard N, Milpied N, Yakoub-Agha I, Koh M, Kröger N, Nagler A, Koc Y, Dietrich S, Montoto S, Dreger P. Long term outcome analysis demonstrates the curative potential of reduced intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transplant. 2018 May;53(5):617-624.

Vargas FA, FurnessAJS, Litchfield K, Joshi K, Rosenthal R, Ghorani E,Solomon I, Lesko MH, Ruef N, Henry JY, Roddie C, Spain L, Aissa AB, Georgiou A, Wong YNS, Smith M, Strauss D, Hayes A, Mårtensson L, Teige I, Frendéus B, Pule M, Marafioti T, Gore M, Larkin J, Turajlic S, Swanton C, Quezada SA, Peggs KS.*Fc effector function contributes to the activity of human anti-CTLA-4 antibodies. Cancer Cell 2018 Apr 9;33(4):649-663.

Peggs KS. Should all patients with Hodgkin Lymphoma who relapse after autologous SCT be considered for allogeneic SCT? Blood Adv. 2018 Apr 10;2(7):817-820.

Bazarbachi A, Boumendil A, Finel H, Mohty M, Castagna L, Peggs KS, Blaise D, Afanasyev B, Diez-Martin JL, Sierra J, BloorA, Martinez C, Robinson S, Craddock C, El-Cheikh J, Corradini C, Montoto S, DregerP, Sureda A. Brentuximab vedotin prior to allogeneic hematopoietic cell transplantation in classical Hodgkin lymphoma: a retrospective study of the EBMT Lymphoma Working Party. Br J Haematol. 2018 Apr;181(1):86-96.

Fox TA, Chakraverty R, Burns S, Carpenter B, Thomson K, Lowe D, Fielding AK, Peggs K, Kottaridis P, Uttenthal B, Bigley V, Buckland M, Grandage V, Denovan S, Grace S, Dahlstrom J, Workman S, Symes A, Mackinnon S, Hough RE, Morris, EC. Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency. Blood. 2018 Feb 22;131(8):917-931.

Natori Y, Alghamdi A, Tazari M, Miller V, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, Humar A; CMV Consensus Forum. Use of viral load as a surrogate marker in clinical studies of cytomegalovirus in solid organ transplantation: a systematic review and meta-analysis. Clin Infect Dis. 2018 Feb 1;66(4):617-631.

Ghorani E, Rosenthal R, McGranahan N, Reading JL, LynchM, Peggs KS, Swanton C, Quezada SA. Differential binding affinity of mutated peptides for MHC class I is a predictor of survival in advanced lung cancer and melanoma. Ann Oncol. 2018 Jan 1;29(1):271-279.

Joshi K, Chain BM, Peggs KS, Quezada SA. The "Achilles Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. Cold Spring Harb Perspect Med. 2018 Jan;8(1). PMID:28630228

Maciocia PM, Wawrzyniecka PA, Philip B, Ricciardelli I, Akarca AU, Onuoha SC, Legut M, Cole DK, Sewell AK, Gritti G, Somja J, Piris MA, Peggs KS, Linch DC, Marafioti T, Pule MA. Targeting the T cell receptor ?-chain constant region for immunotherapy of T cell malignancies. Nat Med. 2017 Dec;23(12):1416-1423.

Eyre TA, Phillips B, Linton KM, Kassam S, Gibb, AlliboneAS, Radford J, PeggsKS, Burton C, Stewart G, LeDieu R, Booth C, Osborne WL, Miall F, Eyre DW, Ardeshna KM, Collins GP. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the pre-transplant naive setting. Br J Haematol. 2017 Nov;179(3):471-479.

Martínez C, Gayoso J, Canals C, Finel H, Peggs K, Dominietto A, Castagna L, Afanasyev B, Robinson S, Blaise D, Corradini P, Itälä-Remes M, Bermúdez A, Forcade E, Russo D, Potter M, McQuaker G, Yakoub-Agha I, Scheid C, Bloor A, Montoto S, Dreger P, Sureda A. Post-transplant cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the EBMT. J Clin Oncol. 2017 Oct 20;35(30):3425-3432.

Roddie C, Peggs KS. Immunotherapy for transplantation-associated viral infections. J Clin Invest. 2017 Jun 30;127(7):2513-2522.

Wong YNS, Joshi K, Pule M, Peggs KS, Swanton C, Quezada SA, Linch M. Evolving adoptive cellular therapies in urological malignancies. Lancet Oncol. 2017 Jun;18(6):e341-e353.

Jamal-Hanjani M, et al. Tracking the Evolution of Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Jun 1;376(22):2109-2121.

Miller PD, de Silva TI, Skinner R, Gilleece M, Peniket A, Hamblin A, Greenfield D, Anthias C, Peggs K, Madrigal A, Snowden JA. Routine vaccination practice after adult and paediatric allogeneic haematopoietic stem cell transplant: a survey of UK NHS programmes. Bone Marrow Transplant. 2017 May;52(5):775-777.

Green K, Pearce K, Sellar RS, Jardine L, Nicolson PL, Nagra S, Bigley V, Jackson G, Dickinson AM, Thomson K, Mackinnon S, Craddock C, Peggs KS, Collin M. The impact of alemtuzumab scheduling on graft versus host disease following unrelated donor fludarabine and melphalan allografts. Biol Blood Marrow Transplant. 2017 May;23(5):805-812.

Vargas FA, Furness AJS, Solomon I, Joshi K, Mekkaoui L, Lesko M, RotaEM, Dahan R, O’Brien T, Nicol D Challacombe B, Turajlic S, Gore M, LarkinJ, Swanton S, Chester KA, Pule M, Ravetch JV, Marafioti T, Quezada SA,. Peggs KS.* Depletion of tumor-infiltrating regulatory T cells with anti-CD25 requires Fc-optimization and synergizes with PD-1 blockade to eradicate established tumors. Immunity. 2017 Apr 18;46(4):577-586.

Abbosh C, …. Peggs KS, Van Loo P, Dive C, Lin CJ, Rabinowitz M, Aerts HJWL, Hackshaw A, Shaw JA, Zimmermann BG; TRACERx consortium; PEACE consortium, Swanton C. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017 Apr 26;545(7655):446-451.

Radford J, McKay P, Malladi R, Johnson R, Bloor A, Percival F, Sureda A, Peggs KS. Treatment pathways and resource use associated with recurrent Hodgkin lymphoma after autologous stem cell transplantation. Bone Marrow Transplant. 2017 Mar;52(3):452-454.

Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, Butler K, Rivat C, Wright G, Somana K, Ghorashian S, Pinner D, Ahsan G, Gilmour K, Lucchini G, Inglott S, Mifsud W, Chiesa R, Peggs KS, Chan L, Farzeneh F, Thrasher AJ, Vora A, Pule M, Veys P.Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017 Jan 25;9(374).

Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, Bacigalupo A, Socié G, Bonifazi F, Finel H, Velardi A, Potter M, Bruno B, Castagna L, Malladi R, Russell N, Sureda A. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol. 2016 Dec;27(12):2251-57.

Kothari J, Foley M, Peggs KS, Mackenzie S, Thomson K, Morris E, Ardeshna KM, Virchis AE, Linch DC, Lambert J. A retrospective comparison of toxicity and initial efficacy of two autologous stem cell transplant conditioning regimens for relapsed lymphoma: LEAM and BEAM. Bone Marrow Transplant. 2016 Oct;51(10):1397-99.

Mock U, Nickolay L, Philip B, Cheung GW, Zhan H, Johnston IC, Kaiser AD, Peggs K, Pule M, Thrasher AJ, Qasim W. Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy.2016 Aug;18(8):1002-11.

Reyal Y, Kayani I, Bloor AJC, Fox CP, Chakraverty R, Sjursen AM, Fielding AK, Taylor MB, BishtonMJ, Morris EC, Thomson KJ, Russell N, Mackinnon S, Peggs KS. Impact of pre-transplantation [18-F]FDG-PET on survival outcomes following T-cell depleted allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transplant. 2016 Jul;22(7):1234-41.

Chaganti S, Illidge T, BarringtonvS, Mckay P, Linton K, Cwynarski, K, McMillan A, Davies A, Stern S, Peggs K. Guidelines for the management of diffuse large B-cell lymphoma. Br J Haematol. 2016 Jul;174(1):43-56.

Furness AJS, Quezada SA, Peggs KS. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade? Immunotherapy. 2016 Jun;8(7):763-6.
Menger L, Sledzinska A, Bergerhoff K, Vargas FA, Smith J, Poirot L, Pule M, Hererro J, Peggs KS, Quezada SA. TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T-cell persistence and rejection of established tumors. Cancer Res. 2016 Apr 15;76(8):2087-93.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, Watkins TB, Shafi S, Murugaesu N, Mitter R, Akarca AU, Linares J, Marafioti T, Henry JY, Van Allen EM, Miao D, Schilling B, Schadendorf D, Garraway LA, Makarov V, Rizvi NA, Snyder A, Hellmann MD, Merghoub T, Wolchok JD, Shukla SA, Wu CJ, Peggs KS, Chan TA, Hadrup SR, Quezada SA, Swanton C. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016 Mar 25;351(6280):1463-9.

Hough R, Danby R, Russell N, Marks D, Veys P, Shaw B, Wynn R, Vora A, Mackinnon S, Peggs KS, Crawley C, Craddock C, Pagliuca A, Cook G, Snowden JA, Clark A, Marsh J, Querol S, Parkes G, Braund H, Rocha V. Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: an update on cord blood unit selection, donor selection algorithms and conditioning protocols. Br J Haematol. 2016 Feb;172(3):360-70.

Marzolini MAV, Thomson KJ, Peggs KS. Antifungal stewardship: towards defining safe stopping criteria for therapeutic oral azoles. Br J Haematol. 2016 Jan;172(2):285-7.
Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SG, Madrigal JA, Rakyan VK, Peggs KS, Beck S. A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. Genome Med. 2015 Dec;7(1):128.

A, Menger L, Bergerhoff K, Peggs KS, Quezada SA. Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy. Mol Oncol. 2015 Dec;9(10):1936-65.

Menger L, Gouble A, Marzolini MA, Pachnio A, Bergerhoff K, Henry JY, Smith J, Pule M, Moss P, Riddell SR, Quezada SA, Peggs KS. TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells. Blood. 2015 Dec;126(26):2781-9. Plenary paper.

Peggs KS. Recent advances in antibody-based therapies for Hodgkin Lymphoma. Br J Haematol. 2015 Oct;171(2):171-78.

Gohil SH, Ardeshna K, Lambert JM, Pule M, Mohamedbhai S, Virchis A, Morris E, Linch DC, Thomson K, Peggs KS. Autologous stem cell transplantation outcomes in elderly patients with B cell Non-Hodgkin's lymphoma. Br J Haematol. 2015 Oct;171(2):197-204.

Poirot L, Philip B, Schiffer-Mannioui C, Le Clerre D, Chion-Sotinel I, Derniame S, Bas C, Potrel P, Lemaire L, Duclert A, Galetto R, Lebuhotel C, Eyquem J, Cheung GW, Gouble A, Arnould S, Peggs KS, Pule M, Scharenberg A, Smith J. Multiplex genome edited T-cell manufacturing platform for "off-the-shelf" adoptive T-cell immunotherapies. Cancer Res. 2015 Sep;75(18):3853-64.
Martin-Liberal J, Furness AJ, Joshi K, Peggs KS, Quezada SA, Larkin J. Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother. 2015 Jun;64(6):765-7.

Marzolini M, Quezada S, Peggs KS. Checkpoint blockade in cancer immunotherapy: squaring the circle. European Medical Journal Oncology. 2015 Mar;3(1):70-76.

Naccache SN, Peggs KS, Mattes FM, Phadke R, Garson JA, Grant P, Samayoa E, Federman S, Miller S, Lunn MP, Gant V, Chiu CY. Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next generation sequencing. Clin Infect Dis. 2015 Mar;60(6):919-23.

Nicholson E, Peggs KS. Cytomegalovirus-specific T cell therapies: current status and future prospects. Immunotherapy. 2015 Feb;7(2):135-146.

Sellar RS, Vargas FA, Henry JY, Verfuerth S, Charrot SC, Beaton B, Chakraverty R, Quezada SA, Mackinnon S, Thomson KJ, Peggs KS. CMV promotes recipient T-cell immunity following reduced intensity T-cell depleted HSCT significantly modulating chimerism status. Blood. 2015 Jan;125(4):731-9.

Boeckh M, Murphy WJ, Peggs KS. Recent advances in cytomegalovirus: an update on pharmacologic and cellular therapies. Biol Blood Marrow Transplant. 2015 Jan;21(1):24-29.

Marzolini M, Peggs KS. Allografting in Hodgkin lymphoma: SCT strategies. J OncoPathology. 2014 Nov; 2(4):107-115.

Quezada SA, Peggs KS. An anti-tumor boost to TH9 cells. Nature Immunol. 2014 Aug; 15(8):703-705.

Philip BM, Kokalaki E, Thomas S, Straathof K, Flutter BR, Marin V, Marafioti T, Chakraverty R, Linch D, Quezada S, Peggs KS, Pule M. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood. 2014 Aug; 124(8):1277-87

Sellar R, Peggs KS. Therapeutic strategies for the prevention and treatment of cytomegalovirus infection: a focussed update. Expert Opin Biol Ther. 2014 Aug; 14(8):1121-1126.